GlobalRPh RX List - ZITUVIMET XR
- Product / population
- ZITUVIMET XR fixed combination; not immediate-release ZITUVIMET.
- Renal measure
- Indexed eGFR, mL/min/1.73 m2; initiation endpoint wording differs between sections.
RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.
Renal dosing, restrictions and evidence limits
The source contraindicates use below indexed eGFR 30. Its warning section discourages initiation at 30 to below 45, while the dosage section prints 30-45 without the same endpoint qualifier. If an established patient falls below 45, reassess benefit versus risk and limit sitagliptin to 50 mg once daily; the below-30 contraindication still applies. Confirm the initiation endpoint rather than silently rounding at 45. Check renal function before treatment and periodically. Keep initiation, continuation, contrast interruption and the immediate-release product distinct.